GLP1R and pancreatic neoplasm: Ultimately, our analysis did not find an association of GLP-1 analogue use with pancreatic cancer in a mena follow-up of 1.74 years, and a sufficient number of patients have been randomized to be able to exclude a NNH of more than 1000 patients.